ArticleClinical journal of gastroenterology2026
A case of dramatic response to pembrolizumab monotherapy in dMMR unresectable colorectal cancer diagnosed following abdominal hemorrhage due to segmental arterial mediolysis.
Article in Clinical journal of gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We present a case of mismatch repair deficient (dMMR) descending colon cancer complicated by peritoneal dissemination and adjacent organ invasion, initially considered unresectable. The patient, a 68-year-old male, experienced acute intra-abdominal hemorrhage due to spontaneous rupture of a pseudoaneurysm from segmental arterial mediolysis (SAM). Emergency surgery confirmed unresectability, prompting immunotherapy with pembrolizumab. Remarkably, after four cycles, significant tumor regression allowed for curative resection, with complete pathological response. Immunohistochemistry revealed a high density of tumor-infiltrating CD8 + T cells and PD-L1-positive stromal cells, indicating robust immune activation. This case underscores immunotherapy's emerging role in converting unresectable dMMR colorectal cancer into resectable disease. This highlights the significance of multidisciplinary management, incorporating immunotherapy, surgical interventions, and vascular assessment to optimize clinical outcomes in dMMR colorectal cancer complicated by vascular pathologies such as SAM. Further investigation into the relationship between vascular pathologies, such as SAM, and malignancy is warranted.
Indexed as
Identifiers
41370027What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.